Erythropoietin is a growth regulating hormone that stimulates the production of red blood cells. Red blood cells are produced in bone marrow and help in carrying oxygen throughout the body. Erythropoietin drugs are used to treat anemia caused due to chronic kidney diseases, cancer treatment or HIV. There are different types of erythropoietin drugs available in market such as Procrit, Epogen and Aranesp. Epogen is the first blockbuster biologic for anemia by Amegen approved by the FDA and is widely used. Rising prevalence of renal diseases, cancer and HIV is the major driving factor of erythropoietin drugs market.

The report titled “Erythropoietin Drugs Market - Growth, Future Prospects and Competitive Analysis, 2023–2030” offers strategic insights into the overall erythropoietin drugs market along with the market size and estimates for the duration of 2020 to 2030. The said research study covers in-depth analysis of multiple market segments based on type of drug, application and different geographies. The product types studied for analyzing the overall global erythropoietin drugs market are majorly segmented into epoetin-alfa, epoetin-beta, darbepoetin-alfa and others. The global erythropoietin drugs market is segmented by application type into cancer, hematology, renal diseases and neurology.

Market size and forecast for these regional and country level markets are presented in this study for the period 2020-2030. Market growth rates for the forecast period 2023-2030 are also included in this report, considering 2021 as the base year. Further cross-sectional presented in terms of drug type, applications and constituent region/country level markets is also included in this section.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global erythropoietin drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global erythropoietin drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global erythropoietin drugs market. In-depth competitive environment analysis and historical (2020) market size data are also provided in the report. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the vascular grafts market. The key players profiled in this report are Amgen, Inc., Biocon Limited, Celltrion, Inc., Dr. Reddy’s Laboratories Ltd., F. Hoffman-La Roche Ltd., Hospira, Inc., Intas Pharmaceuticals Ltd., Johnson & Johnson, Inc., LG Life Sciences Ltd., Ranbaxy Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and others.

Currently, kidney disorders occupy a large share of the global erythropoietin drugs application market, due to rising incidence of renal diseases. Amgen’s blockbuster drug Epogen was the first approved by FDA for treatment of anemia arising due to chronic kidney diseases. Therefore, being the first in the market and high adoption rate led to dominance of kidney disorders in the market. Anemia occurring due to cancer and HIV is the fastest growing segment of erythropoietin drugs market. Rising prevalence of cancer and corresponding high usage of chemotherapy treatment that causes reduction in the count of RBCs is commonly observed phenomenon that fuels the demand of global erythropoietin drugs market.

Epoetin-alfa occupies the largest revenue share and dominates the global erythropoietin drugs market. Amgen’s Epogen (Epoetin–alfa) was the first billion dollar product of biotech industry that is widely used by physicians. It is the first biologic drug approved for treatment of anemia occurring due to cancer, HIV and chronic kidney disease. Epoetin-beta, a recombinant of Epo-alpha, also occupies significant share, due to better efficacy than alpha. Darbepoetin alfa is anticipated to be the fastest growing segment in the forecast period 2023-2030. It is also an Amgen product branded as Aranesp, a higher version of Epogen, with minimum side effect and high potency. With patent expiration, the biologics segment will decline, paving way to biosimilars in the market.

In 2021, North America dominates the erythropoietin drugs market followed by Europe. Rising prevalence of chronic kidney diseases, cancer and HIV is the key reason for growth observed in erythropoietin drugs market in this region. According to the National Chronic Kidney Diseases fact sheet, around 15% of US adult suffer from CKD. Around 1.1 million people in U.S. are living with HIV, which bear a huge burden of mortality and morbidity. Well established healthcare infrastructure, and favorable reimbursement policies for chronic diseases, extensive research and development for novel drugs are some of the major factors that further fuels the growth of erythropoietin drugs market in North America. Most of the key players are based out of this region and are strategically expanding and strengthening distribution network thus raising their revenue share. Asia Pacific is anticipated to be the fastest growing market in the forecast period 2023-2030. Asia Pacific is base to huge population pool that is perpetually growing, thus there is a corresponding increase in incidence of chronic diseases that would further lead to demand for low cost drugs. Hence, Asia Pacific would be the most lucrative market for upcoming biosimilars producing companies. Further with improving healthcare infrastructure, government funding would drive the erythropoietin drugs market.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Erythropoietin Drugs market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Erythropoietin Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Erythropoietin Drugs market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Erythropoietin Drugs market?
• Which is the largest regional market for Erythropoietin Drugs market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Erythropoietin Drugs market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Erythropoietin Drugs market worldwide?